Actively Recruiting
Phase III Study Comparing BL-M07D1 and Pembrolizumab-Platinum Chemotherapy for First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
Led by Sichuan Baili Pharmaceutical Co., Ltd. · Updated on 2025-11-17
440
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of BL-M07D1 compared to pembrolizumab-platinum chemotherapy as a first-line treatment in patients with HER2-mutant advanced or metastatic non-squamous non-small cell lung cancer. This phase III, randomized, open-label, multicenter study focuses on adults aged 18 to 75 years who have confirmed HER2 mutations in their cancer and measurable tumors. Participants receive either BL-M07D1 or pembrolizumab combined with pemetrexed and carboplatin or cisplatin, administered by intravenous infusion every three weeks in treatment cycles. Those benefiting from treatment may continue receiving additional cycles until disease progression, intolerable side effects, or other reasons for stopping treatment occur. Throughout the study, researchers will monitor participants for up to approximately 24 months, assessing progression-free survival as the primary outcome. Secondary measures include overall survival, response rates, disease control, duration of response, treatment-related adverse events, and the presence of anti-drug antibodies. Participants will undergo various tests and evaluations to track these outcomes and ensure safety during the study period.
CONDITIONS
Brief Title
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
Research Team
S
Sa Xiao, PHD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here